ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 744

Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?

María de la Torre1 and Cecilia Pisoni 1, 1Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: polymyalgia rheumatica and leukocytes

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Recently, the use of hematologic indexes as markers of systemic inflammation has been reported in oncological, cardiovascular and rheumatic diseases. Only 2 studies evaluated their role in polymyalgia rheumatica (PMR).

Our objective was to primarily compare the levels of neutrophil- (NLR), monocyte- (MLR), eosinophil- (ELR), basophil- (BLR) and platelet to lymphocyte ratio (PLR) in PMR and control patients without inflammatory conditions and, secondarily, to evaluate their use as prognostic markers in PMR.

Methods: This retrospective case control study included 63 patients with PMR and 101 patients without inflammatory conditions who attended our Hospital. Clinical data and blood cell counts at diagnosis (prior to start treatment) were obtained from medical records and laboratory reports.

We compared the indexes of both groups at diagnosis by a Student’s t test and sequentially performed a subgroup analysis in PMR patients in order to determinate the utility of the indexes to evaluate prognosis, relapses and recurrences. We also analyzed the use of methotrexate as a marker of more severe disease. A correlation with inflammatory markers using Student’s t test and Pearson correlation coefficient was performed

Results: Age, gender and laboratory data of PMR and control patients are shown in Table 1. The control group included patients with osteoarthritis (78,2%), fibromyalgia (9.9%) and others soft tissue non inflammatory conditions (11.9%). NLR and MLR levels were significantly higher in PMR patients than controls (NLR 2.77 vs 1.99, p < 0.001 and MLR 0.37 vs 0.27, p < 0.001). All the other indexes did not differ between populations. Clinical characteristics of PMR patients are shown in Table 2. The median time of follow up of PMR patients was 24.1 months (IQR 10.5-35.3).  When evaluating this subgroup of patients, neither NLR nor MLR were associated with relapses, recurrences or need of methotrexate during follow up. Results shown in table 3. No correlation was found between both indexes and the duration of symptoms before diagnosis and duration of glucocorticoid treatment. The median erythrocyte sedimentation rate (ESR) was 41.5 mm/hr (19 – 62) and C reactive protein (CRP) level was 2.48 mg/L (0.54 – 3.38) at diagnosis. We found a poor correlation between NLR and MLR and ESR and CRP levels. Fourteen PMR patients (22.2%) had normal values of ESR and CRP. However, the treating physician considered the diagnosis on a clinical basis and started treatment accordingly. When comparing NLR and MLR levels, there were no differences between this group and control patients; on the other hand, a significant difference was found with PMR patients who presented with high levels of acute phase reactants.

Conclusion: NLR and MLR levels were significantly higher in PMR patients than controls. Baseline indexes did not correlate adequately with acute phase reactants and they were not able to predict a poor outcome in PMR.


table 1 pmr

Table 1. Age, gender and laboratory date of both populations


table 2 pmr

Table 2. Characteristics of PMR patients


NLR

Table 3. Comparison of NLR in PMR patients based on relapses, recurrences and use of methotrexate


Disclosure: M. de la Torre, None; C. Pisoni, None.

To cite this abstract in AMA style:

de la Torre M, Pisoni C. Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-hematologic-indexes-helpful-in-the-diagnosis-and-prognosis-of-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-hematologic-indexes-helpful-in-the-diagnosis-and-prognosis-of-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology